RFC1

Replication factor C subunit 1 · P35251 · RFC1 on Sugi Atlas →

0 patent compounds predicted against RFC1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to RFC1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery PHASE1/PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers PHASE1/PHASE2COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Treatment of Ectopic Calcification in Fahr's Disease or Syndrome PHASE2RECRUITING
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer PHASE1/PHASE2COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) nanCOMPLETED
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS nanRECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Assessing Colonic Folate Absorption & Metabolism nanUNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
Sodium Transport: Genetics and Hypertension nanCOMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS nanRECRUITING
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications nanUNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
Genetic Predictors of Incident Cardiovascular Disease nanWITHDRAWN
Mayo AVC Registry and Biobank nanRECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RFC1 binder may also engage these)

ProteinNameSimilarity
P35601 1.000 P35601 →
P35600 0.996 P35600 →
P30181 0.995 P30181 →
O60182 0.994 O60182 →
Q9FJ79 0.993 Q9FJ79 →
Q9C587 0.993 Q9C587 →
Q9DF36 0.993 Q9DF36 →
A3KFM7 0.992 A3KFM7 →
Q9C813 0.992 Q9C813 →
Q9VCP0 0.992 Q9VCP0 →
D3ZA12 0.992 D3ZA12 →
Q9P7C7 0.992 Q9P7C7 →
DHX29 ATP-dependent RNA helicase DHX29 0.992 landscape →
Q9M358 0.992 Q9M358 →
Q2R2B4 0.992 Q2R2B4 →
B6ZLK2 0.991 B6ZLK2 →
Q09811 0.991 Q09811 →
Q19546 0.991 Q19546 →
O42905 0.991 O42905 →
P38630 0.991 P38630 →
Q21037 0.991 Q21037 →
Q04692 0.991 Q04692 →
O43078 0.991 O43078 →
O94667 0.991 O94667 →
A7A0P8 0.991 A7A0P8 →
B5VE38 0.991 B5VE38 →
Q9QZ11 0.991 Q9QZ11 →
Q9VTE6 0.991 Q9VTE6 →
C5H8J1 0.991 C5H8J1 →
B0R061 0.990 B0R061 →